Targeted therapeutics based on engineered proteins that bind EGFR

Patent metadata

Field	Value
Publication number	US-9234028-B2
Application number	US-201313956952-A
Country	US
Kind code	B2
Filing date	Aug 1, 2013
Priority date	Feb 14, 2008
Publication date	Jan 12, 2016
Grant date	Jan 12, 2016

Abstract

The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

First claim

The invention claimed is:

1. A polypeptide comprising a tenth fibronectin type III ( 10 Fn3) domain, wherein the 10 Fn3 domain (i) comprises an AB loop, a BC loop, a CD loop, a DE loop, an EF loop, and an FG loop, wherein the amino acid sequences of the BC, DE, and FG loops are identical to the amino acid sequences of the respective BC, DE, and FG loops of an 10 Fn3 domain with an amino acid sequence selected from the group consisting of SEQ ID NOs: 207-231; and (ii) binds human epidermal growth factor receptor (EGFR) with a disassociation constant of less than 10 −4 M.

2. The polypeptide of claim 1 , wherein the 10 Fn3 domain binds human EGFR with a dissociation constant of less than 10 −6 M.

3. The polypeptide of claim 1 , further comprising one or more pharmacokinetic (PK) moieties selected from: a polyoxyalkylene moiety, a human serum albumin binding protein, sialic acid, human serum albumin, IgG, an IgG binding protein, transferrin, and an Fc fragment.

4. The polypeptide of claim 3 , wherein the PK moiety is the polyoxyalkylene moiety and said polyoxyalkylene moiety is polyethylene glycol.

5. The polypeptide of claim 3 , wherein the PK moiety and the 10 Fn3 domain are operably linked via at least one disulfide bond, a peptide bond, a polypeptide, a polymeric sugar, or a polyethylene glycol moiety.

6. The polypeptide of claim 3 , wherein the PK moiety and the 10 Fn3 domain are operably linked via a polypeptide comprising the amino acid sequence of SEQ ID NOs: 232-235.

7. The polypeptide of claim 1 , further comprising a second domain selected from: an antibody moiety; a derivative of lipocalin; a derivative of tetranectin; an avimer; a derivative of ankyrin; and a second fibronectin type III (Fn3) domain, wherein the second domain binds to a human protein, and wherein the second Fn3 domain (i) comprises an AB loop, a BC loop, a CD loop, a DE loop, an EF loop, and an FG loop; (ii) has at least one loop selected from loop BC, DE, and FG with a randomized amino acid sequence relative to the sequence of the corresponding loop of the human Fn3 domain, and (iii) binds a human protein that is not bound by the human Fn3 domain.

8. The polypeptide of claim 7 , wherein the second domain is a second Fn3 domain, and wherein the second Fn3 domain binds the human protein with a disassociation constant of less than 10 −4 M.

9. The polypeptide of claim 7 , wherein the second domain is a second Fn3 domain, and wherein the second Fn3 domain is a tenth fibronectin type III domain ( 10 Fn3).

10. The polypeptide of claim 9 , wherein the second 10 Fn3 domain comprises a polypeptide selected from:
(i) a polypeptide comprising the amino acid sequence of any of one of SEQ ID NOS: 2-231 and 236; and
(ii) a polypeptide comprising the amino acid sequence at least 90% identical to any of one of SEQ ID NOS: 2-231 and 236.

11. The polypeptide of claim 7 , wherein the 10 Fn3 domain and the second domain are operably linked via at least one disulfide bond, a peptide bond, a polypeptide, a polymeric sugar, or a polyethylene glycol moiety.

12. The polypeptide of claim 7 , wherein said polypeptide inhibits the binding of transforming growth factor alpha (TGF-alpha) or epidermal growth factor (EGF) to EGFR and does not activate human EGFR at sub IC 50 concentrations in a cell-based assay.

13. The polypeptide of claim 1 , wherein said polypeptide has been deimmunized to remove one or more T-cell epitopes.

14. The polypeptide of claim 1 , wherein said polypeptide inhibits total EGF-stimulated phosphotyrosine activation of EGFR with an IC 50 of less than 10 μM.

15. The polypeptide of claim 1 , wherein said polypeptide inhibits ERK phosphorylation with an IC 50 of less than 10 μM.

16. The polypeptide of claim 1 , wherein said polypeptide inhibits AKT phosphorylation with an IC 50 of less than 10 μM.

17. A pharmaceutically acceptable composition comprising the polypeptide of claim 1 , wherein the composition is essentially endotoxin free.

18. A polypeptide comprising a tenth fibronectin type III ( 10 Fn3) domain, wherein the 10 Fn3 domain (i) comprises an AB loop, a BC loop, a CD loop, a DE loop, an EF loop, and an FG loop; (ii) comprises an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 207-231; and does not comprise an integrin binding motif comprising arginine-glycine-aspartic acid (RGD).

19. The polypeptide of claim 18 , wherein the polypeptide comprises an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 207-231.

Assignees

• Bristol Myers Squibb Co

Inventors

• Camphausen Ray
• Morse Brent
• Emanuel Stuart
• Fabrizio David

Classifications

• A61P35/02

  specific for leukemia · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• C07K14/765

  Serum albumin, e.g. HSA · CPC title

• C07K2318/20

  Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics · CPC title